Overview

Drug Interaction Oral Contraceptive Pill (OCP)

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) in healthy female subjects
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Asunaprevir
Contraceptive Agents
Contraceptives, Oral
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination